-

Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

To listen to the conference call, please dial (866) 374-5140 (US/Canada) or (404) 400-0571 (International) and use the confirmation number "41691074#" approximately five minutes prior to the start time.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Versions
English

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and...

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,...
Back to Newsroom